Vertex Pharmaceuticals Incorporated
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2015-08-28
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 93
- Registration Number
- NCT00865904
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
- Conditions
- Healthy
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2009-02-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 72
- Registration Number
- NCT00789126
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 540
- Registration Number
- NCT00758043
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1095
- Registration Number
- NCT00627926
Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-04-04
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT00623649
- Locations
- 🇺🇸
The Liver INstitute at Methodist Dallas, Dallas, Texas, United States
🇺🇸Alamo Medical Research, San Antonio, Texas, United States
🇨🇦Ottawa Hospital - General Campus, Ottawa, Ontario, Canada
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 117
- Registration Number
- NCT00535847
- Locations
- 🇺🇸
Kaiser Permanente Internal Medicine, San Diego, California, United States
🇺🇸University of Colorado Health Sciences Center, Denver, Colorado, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
Study of Telaprevir in Subjects With Hepatic Impairment
- Conditions
- Hepatic Insufficiency
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2008-10-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Registration Number
- NCT00509210
- Locations
- 🇺🇸
Indiana University, Department of Medicine,Division of Gastroenterology / Hepatology, Indianapolis, Indiana, United States
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT00500812
- Locations
- 🇺🇸
St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States
🇺🇸University of Cincinnati Mayfield Clinic and Spine Institute, Cincinnati, Ohio, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT00493441
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸California Pacific Medical Center Research Institute, San Francisco, California, United States
Safety Study of Ivacaftor in Subjects With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 39
- Registration Number
- NCT00457821
- Locations
- 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
🇺🇸The Children's Hospital, Aurora, Colorado, United States